Free-from-progression period and overall short preoperative immunotherapy with IL-2 increases the survival of pancreatic cancer patients treated with macroscopically radical surgery

R. Caprotti, F. Brivio, L. Fumagalli, C. Nobili, L. Degrate, P. Lissoni, D. Parolini, G. Messina, M. Colciago, M. Scotti, F. Uggeri

Research output: Contribution to journalArticle

Abstract

Background: The treatment of pancreatic cancer is still rudimentary, even in the case of locally limited tumors, because of the high frequency of recurrence due to severe suppression of the anticancer immunity that is further amplified by surgery-induced immunosuppression, evidenced by a decline in lymphocyte numbers during the postoperative period. Previous studies in colorectal cancer demonstrated that surgery-induced lymphocytopenia may be abrogated by a brief preoperative administration of IL-2. Materials and Methods: The study included 30 consecutive patients who were randomized to be treated by radical surgery alone as a control group or by a preoperative immunotherapy with IL-2 (12 MIU/day SC for 3 consecutive days) plus surgery. Results: Mean lymphocyte numbers significantly decreased in patients treated with surgery only, whereas it significantly rose in the IL-2-treated group. After a follow-up of 36 months, both the free-from-progression period (FFPP) and the overall survival were significantly higher in patients treated with IL-2. Conclusion: These preliminary results suggest that a short-period preoperative immunotherapy with IL-2 is sufficient to modify host tumor interactions in operable pancreatic cancer, with a subsequent abrogation of postoperative lymphocytopenia and a prolongation of FFPP and overall survival time.

Original languageEnglish
Pages (from-to)1951-1954
Number of pages4
JournalAnticancer Research
Volume28
Issue number3 B
Publication statusPublished - May 2008

Keywords

  • Immunosurgery
  • Immunotherapy
  • Interleukin-2
  • Lymphocytopenia
  • Pancreatic cancer

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Free-from-progression period and overall short preoperative immunotherapy with IL-2 increases the survival of pancreatic cancer patients treated with macroscopically radical surgery'. Together they form a unique fingerprint.

  • Cite this

    Caprotti, R., Brivio, F., Fumagalli, L., Nobili, C., Degrate, L., Lissoni, P., Parolini, D., Messina, G., Colciago, M., Scotti, M., & Uggeri, F. (2008). Free-from-progression period and overall short preoperative immunotherapy with IL-2 increases the survival of pancreatic cancer patients treated with macroscopically radical surgery. Anticancer Research, 28(3 B), 1951-1954.